Function Health’s $298M Bet on Preventive Care: Unit Economics, Competitive Dynamics, and the Quest for Scale
Welcome to Healthcare Markets & Technology.
Rigorous analysis of AI, policy, capital, technology, and clinical operations across U.S. healthcare — written for the people who build, invest in, and lead it.
Free subscribers get 2 public articles per week. Upgrade to paid → for the full 7 articles/week, paid podcast episodes, deal breakdowns, and the complete 538-deep-dive archive.
Subscribe or upgrade here →
One thing to bookmark: the searchable Knowledge Base at kb.onhealthcare.tech isn’t in Substack’s menu. Save it now — on mobile, tap share → “Add to Home Screen.”
Reply to any email with questions. I read every one.
— Trey
ABSTRACT
Function Health recently closed a $298 million Series B at a $2.5 billion valuation, one of the largest rounds in direct-to-consumer healthcare history. The company offers comprehensive annual lab testing packages for $499 per year, promising to track over 100 biomarkers with quarterly testing and physician consultations. This essay examines:
• Function’s business model and unit economics, including customer acquisition costs, lifetime value projections, and margin structure
• The implications of a $2.5B valuation for required growth trajectories and exit expectations
• Competitive landscape spanning direct-to-consumer lab testing, concierge medicine, and traditional preventive care
• Market sizing and addressable opportunity in the wellness-focused consumer segment
• Key risk factors including regulatory challenges, medical necessity standards, and insurance integration questions
• Growth trajectories and scenarios that could determine whether Function becomes a decade-defining healthcare company or a cautionary tale about late-stage venture excess
The analysis suggests Function’s success hinges on three critical factors: scaling to multi-million member count while maintaining reasonable CAC, achieving 70%+ annual retention to justify customer lifetime value assumptions that support the valuation, and potentially pivoting to B2B or insurance channels without undermining their DTC positioning.
TABLE OF CONTENTS
Introduction and the $2.5B Question
The Function Health Model Explained
Breaking Down the Unit Economics
What a $2.5B Valuation Actually Means
Competitive Landscape and Market Positioning
Total Addressable Market and Growth Constraints
The Path to Venture Scale Returns
Risk Factors and Ways This Goes Sideways
Conclusion and Investment Framework
Introduction and the $2.5B Question
Function Health just raised $298 million at a $2.5 billion post-money valuation and the healthcare venture community is either nodding in approval or screaming into the void depending on which chat groups you frequent. This is the kind of round that makes you stop and really interrogate your assumptions about what constitutes a reasonable valuation in consumer healthcare. For context, $2.5B is more than what many profitable healthcare companies with actual revenue scale trade at in the public markets. It’s the kind of number that implies Function isn’t just building a nice business, they’re building something that could fundamentally reshape how Americans think about preventive care.
